EG00229|cas:1210945-69-9|西域试剂

EG00229,98.18%

产品编号：Bellancom-10799| CAS NO：1210945-69-9| 分子式：C₁₉H₂₀F₃N₇O₇S₃| 分子量：611.60

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-10799	￥1400.00	杭州北京（现货）
Bellancom-10799	￥2250.00	杭州北京（现货）
Bellancom-10799	￥8980.00	杭州北京（现货）
Bellancom-10799	￥15400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

EG00229

产品介绍

EG00229 是一种神经纤维蛋白 1 受体 (NRP1) 拮抗剂。EG00229 选择性抑制 VEGF-A 与 NRP1 b1 域的结合， IC₅₀ 为 3μM，但对 VEGFA 与 VEGFR-1 和 VEGFR-2 的结合没有影响。

生物活性

EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC₅₀ of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2.

体外研究

EG00229 (Compound 2; 0-100 μM; 48 hours; A549 cells) treatment causes a significant reduction in cell viability over a 48 hours incubation.
EG00229 (Compound 2) demonstrates inhibition of VEGF-A binding to NRP1 and attenuates VEGFR2 phosphorylation in endothelial cells. Inhibition of migration of endothelial cells is also observed in HUVECs.
EG00229 (Compound 2) selectively inhibits radiolabeled ¹²⁵I-VEGF-A binding to porcine aortic endothelial (PAE)/NRP1, but not VEGFR2-expressing cells, with an IC₅₀ of 8 μM. EG00229 also inhibits VEGF-A binding to lung carcinoma A549 and prostate carcinoma DU145 cells, which express NRP1, but not VEGFR1 and VEGFR2, with similar potency. Binding of VEGF-A to human umbilical vein endothelial cells (HUVECs), which express VEGFR2, VEGFR1, and NRP1, is also inhibited by EG00229 with an IC₅₀ of 23 μM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	A549 cells
Concentration:	0 µM, 10 μM, 30 μM, 100 μM
Incubation Time:	48 hours
Result:	Caused a significant reduction in cell viability.

体内研究
(In Vivo)

EG00229 (0-10 mg/kg; intraperitoneal injection; three times per week; for 4 weeks; NSG mice) treatment substantially reduces tumor growth and visible vascularization.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-week old female NOD scid IL2 receptor gamma chain knockout mice (NSG mice) with ECS cells
Dosage:	0 mg/kg, 10 mg/kg
Administration:	Intraperitoneal injection; three times per week; for 4 weeks
Result:	Reduces tumor growth and visible vascularization.

体内研究

EG00229 (0-10 mg/kg; intraperitoneal injection; three times per week; for 4 weeks; NSG mice) treatment substantially reduces tumor growth and visible vascularization.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-week old female NOD scid IL2 receptor gamma chain knockout mice (NSG mice) with ECS cells
Dosage:	0 mg/kg, 10 mg/kg
Administration:	Intraperitoneal injection; three times per week; for 4 weeks
Result:	Reduces tumor growth and visible vascularization.

体内研究

EG00229 (0-10 mg/kg; intraperitoneal injection; three times per week; for 4 weeks; NSG mice) treatment substantially reduces tumor growth and visible vascularization.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-week old female NOD scid IL2 receptor gamma chain knockout mice (NSG mice) with ECS cells
Dosage:	0 mg/kg, 10 mg/kg
Administration:	Intraperitoneal injection; three times per week; for 4 weeks
Result:	Reduces tumor growth and visible vascularization.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 41.4 mg/mL (67.69 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6351 mL	8.1753 mL	16.3506 mL
5 mM	0.3270 mL	1.6351 mL	3.2701 mL
10 mM	0.1635 mL	0.8175 mL	1.6351 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (4.09 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.09 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.09 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.09 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。